Cogstate Limited (ASX:CGS)
Australia · Delayed Price · Currency is AUD | Market Cap | 365.58M +53.1% |
| Revenue (ttm) | 84.06M +18.8% |
| Net Income | 16.16M +46.7% |
| EPS | 0.09 +44.6% |
| Shares Out | 170.83M |
| PE Ratio | 23.24 |
| Forward PE | 19.60 |
| Dividend | 0.02 (0.94%) |
| Ex-Dividend Date | n/a |
| Volume | 159,468 |
| Average Volume | 88,460 |
| Open | 2.240 |
| Previous Close | 2.140 |
| Day's Range | 2.240 - 2.240 |
| 52-Week Range | 1.210 - 2.970 |
| Beta | 0.06 |
| RSI | 46.00 |
| Earnings Date | Feb 19, 2026 |
About Cogstate
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. It offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer’s disease and dementia, preclinical Alzheimer’s disease, pediatrics and rare disease, Parkinson’s disease, multiple sclerosis, schizophre... [Read more]
Financial Performance
In fiscal year 2025, Cogstate's revenue was $53.09 million, an increase of 22.25% compared to the previous year's $43.43 million. Earnings were $10.14 million, an increase of 86.15%.
Financial numbers in USD Financial StatementsNews
Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer
Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief ...
Cogstate Announces Formation of Scientific Advisory Board
Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate's strategy Leading clinical and scientific experts in neuro...